Welcome to the Fourth 2017 Issue of The CLL Tribune
Another year is coming to a close. And what a year it has been! While there is still no cure for CLL, we’re still learning and making progress. Venetoclax is making headway in the treatment of CLL, with fewer side effects than Ibrutinib for many patients. New promising therapies are on the horizon, and there is hope—hope for a cure.
At the CLL Society, we continue to provide news and insights to these issues and more—through our website (CLLsociety.org), reports and videos from major medical conferences focused on CLL and related blood cancers, this quarterly newsletter, patient and caregiver surveys, and our CLL-specific support groups. We’re now even providing free second opinions through the CLL Society Expert Access pilot program.
And, we believe we’re making a difference. Traffic to the CLL Society website has grown more than 60% in 2017 and the number of unique visitors has doubled. We look forward to the day when no one has a reason to visit CLLSociety.org because a cure has been found. Until that day, however, we’re here for every patient and caregiver that faces the challenges of CLL and related blood cancers.
We hope that you, too, will help support the blood cancer community. We’re all in this together, and together we can make a difference. Please consider a tax deductible donation to the CLL Society today.
By Chau Huynh, MD
The abnormal white blood cells or “leukemic cells” produced in chronic lymphocytic leukemia (CLL) can reside for years in various parts of the body…Read more
Tell us what sections are most important to you, what topics are missing, and what are YOUR educational needs… Read more
By Richard Furman, MD
Dr. Richard Furman of Weill-Cornell Medical College answers readers’ questions submitted to the Q3 2017 issue of The CLL Tribune…Read more
By Brian Koffman, MD and John Pagel, MD, PhD
At the ASH (American Society of Hematology) Annual Meeting and Exposition 2017, we heard not only about new trials, but also learned from retrospective research…Read The Interview
We’d like to thank the supporters of The CLL Tribune:
- Genentech/Biogen Idec
- Sunesis Pharmaceuticals
- TEVA Pharmaceuticals
- TG Therapeutics
The CLL Society does not provide medical advice or endorsements. Unless explicitly stated otherwise, all content in the CLL Tribune is the opinion or information of its author, not the CLL Society. This newsletter is for reference and educational purposes only and is not a substitute for medical advice. We do not guarantee the accuracy of any of the materials. Always contact your own doctor or other professional healthcare provider if you have any questions concerning your or your family’s health. Everyone’s circumstances are different.